GeneMedi knowledge base of Coronavirus disease 2019 (COVID-19): A Collection of reviews, diagnosis protocols, and guidance

COVID-19, a novel pathogenic coronavirus (2019-nCoV or SARS-CoV2) induced disease, emerged in China and spread globally rapidly.

GeneMedi produces kinds of recombinant 2019 nCoV(SARS2 coronavirus) antigens as shown below: Nucleocapsid(N protein), Spike(S protein), RBD, S1+S2 ECD, Envelope (E protein), 3C-like Proteinase. All the recombinant proteins of 2019 nCoV are suitable for in functional ELISA,lateral-flow tests, and other immunoassays.

GeneMedi has submitted a preprints review about COVID-19 and 2019-nCoV.

Click here for the full-text reading:
Viral vector-based vaccine; DNA-based vaccine; RNA based vaccine – A landscape for vaccine technology against infectious disease, COVID-19 and tumor.

An Insight of comparison between COVID-19 (2019-nCoV disease) and SARS in pathology and pathogenesis

Landscape Coronavirus Disease 2019 test (COVID-19 test) in vitro — A comparison of PCR vs Immunoassay vs Crispr-Based test

In the mission of helping global scientists for the development of diagnosis and drug against 2019 nCoV(SARS2 coronavirus), GeneMedi scientists will keep moving.